


Curriculum vitae (November 21)

Name	Philippe Krebs			
Date and place of Birth	May 10 th , 1977; Fribourg (Switzerland)			
Nationality	Swiss			
Marital status	Married to Danielle C.			
Children	Anaïs V. (2010), Lionel F. (2012)			
Private Address	Schaufelgrabenweg 41, CH-3033 Wohlen			
Private e-mail	krebs.philippe@gmail.com			
Cell phone no	+41 79 729 0980	OrcID		0000-0003-4918-6654
Professional e-mail	philippe.krebs@pathology.unibe.ch	ResearcherID		A-3449-2012
Professional phone no	+41 31 632 4971	Google Scholar ID		vnE60MwAAAAJ
Website	http://www.pathology.unibe.ch/research/research_groups/group_krebs/index_eng.html			
Languages	French (mother language), German (excellent, oral and written), English (excellent, oral and written)			

Education / professional experience

Since Oct. 2011	Group leader (Oberassistent 2011-2015; 12.2015-11.2017: Dozent II; since 12.2017: Dozent I) Institute of Pathology, University of Bern, Switzerland
Apr. 2021	Award of the title of Associated Professor; date of award: 01.04.2021
Jun. 2016	Habilitation in Experimental Pathology; date of PD title award: 21.06.2016
2006-2011	Research associate (Prof. Bruce Beutler) The Scripps Research Institute, Department of Genetics, La Jolla, USA EMBO Fellow (24 months), SNSF Fellowship (30 months)
2005-2006	Junior postdoc position (Prof. Burkhard Ludewig) Institute of Immunobiology, Kantonal Hospital, St-Gallen, Switzerland
2001-2005	Ph.D. thesis (Prof. Burkhard Ludewig, Prof. Hans Hengartner and Prof. Rolf Zinkernagel) Institute of Experimental Immunology of the University Hospital Zürich, ETHZ and Institute of Immunobiology, Kantonal Hospital, St-Gallen, Switzerland
1999-2000	Diploma (MSc) thesis (Prof. Sandro Rusconi) Institute of Biochemistry, University of Fribourg, Switzerland
1996-2001	Studies in biochemistry and molecular biology, MSc in biochemistry. University of Fribourg
1992-1996	Collège St-Michel, Fribourg , Type A (ancient Greek / Latin); Award of the best Matura / Baccalauréat

Institutional responsibilities

2012-	Biosafety Officer for research and diagnostics activities at the Institute of Pathology, University of Bern
2012-	Member of the Expert Commission of the Graduate School for Cellular and Biomedical Sciences of the University of Bern; mentor (total of 20 PhD students) and thesis co-advisor (total of 7 PhD students)
2016-	Member of Steering Committee for project on Digital Pathology at the Institute of Pathology (IT solution for analysis, storage and organization of scanned histology slides together with patient- and project-specific data).
2021-	Member of the Committee for the Medical and Pharmaceutical Libraries, University of Bern

Grants and Awards

2021	Main applicant, Swiss Life / Jubiläumsstiftung; 6 months project grant; CHF 20'000
2021	Main applicant, Uniscentia Stiftung; 18 months project grant; CHF 136'000
2020	Main applicant, Bern Center for Precision Medicine (BCPM); 9 months project grant; CHF 40'532
2019	Main applicant, Swiss National Science Foundation ; 48 months project grant; CHF 630'000
2019	Main applicant, Helmut Horten Stiftung ; 18 months grant; CHF 130'000
2018	Main applicant, Seed money project (Swiss Confederation and ETHZ) ; 12 months grant; CHF 10'000
2018	Main applicant, Lungenliga Bern (Bernese Lung League) , 12 months grant; CHF 79'554
2018	Main applicant, Lungenliga Schweiz (Swiss Lung League) , 12 months grant; CHF 79'554
2018	Main applicant, Carigest SA , 12 months grant; CHF 130'000
2018	EU / Marie Skłodowska-Curie RISE (Research and Innovation Staff Exchange) Program, “ <i>DISCOVER / Death receptor signaling in tumor immune editing</i> ”; total: € 904'500; part for group Philippe Krebs (partner): € 67'500 (proportional to the number of staff secondments)
2018	“ <i>Novel cell-based immunization technology and functional validation of resulting antibodies</i> ”

- Coapplicant; **(Swiss) Commission for Technology and Innovation (CTI / Innosuisse)**; 24 months grant; main applicant: J. Rohrer, ZHAW; associated business partner: Memo Therapeutics AG; total: CHF 737'539; part for group Philippe Krebs: **CHF 163'416** (conditional on milestone achievement)
- 2017 “*Apparatus for in vivo molecular imaging at cellular resolution in the intestine of mice*” (Equipment grant; total CHF 376'196). Co-applicant, **Swiss National Science Foundation**, equipment grant (**R'Equip Grant**)
- 2017 Main applicant, **UniBE ID** (Interdisciplinary) **Grants** 2017; 24 months grant; total CHF 150'000; part for group Philippe Krebs: **CHF 75'000**
- 2017 Main applicant, **Kurt und Senta Herrmann Foundation**; 6 months grant; **CHF 30'000**
- 2017 Main applicant, **Swiss Cancer Research Foundation (KFS)**; 30 months grant; **CHF 312'500**
- 2017 Main applicant, Swiss Life / Jubiläumsstiftung; **CHF 30'000**
- 2016 Award from the Bern Immunology Club: "BIC prize – best paper – 2015" (Mager *et al.*, JCI, 2015)
- 2015 Main applicant, **Fondazione San Salvatore**; 24 months project grant; **CHF 120'000**
- 2015 Main applicant, **Swiss National Science Foundation**; 36 months project grant; **CHF 525'000**
- 2015 Main applicant, **Vontobel Foundation**; 18 months project grant; **CHF 130'000**
- 2015 Main applicant, **Olga Mayenfisch Foundation**; 12 months project grant; **CHF 23'000**
- 2015 Co-main applicant with Lukas Mager, MD
Foundation Johanna Dürmüller-Bol; contributing grant; **CHF 20'000**
- 2014 Main applicant, **Swiss Cancer League (SKL)**; 12 months grant; **CHF 124'350**
- 2014 Co-main applicant with Yara Banz, MD, PhD
Stiftung für klinisch-experimentelle Tumorforschung; 12 months grant; **CHF 80'000**
- 2013 Main applicant, **Marie Curie Career Integration Grants (CIG)**; 48 months grant; **€ 100'000**
- 2012 “*Apparatus for Colonoscopy and Endoscopic Manipulations in Mice*” (Equipment grant; total CHF 108'000)
Main applicant, **Swiss National Science Foundation**, equipment grant (**R'Equip Grant**)
- 2012 Main applicant, **Award from the Berne University Research Foundation** (Equipment grant; CHF 16'090)
- 2012 Coapplicant; **Swiss National Science Foundation**; 40 months project grant; CHF 395'391. Collaboration, no money for group Philippe Krebs)
- 2012 Main applicant, **Swiss National Science Foundation**; 36 months project grant; **CHF 377'366**

Total direct grant money raised and received since Oct. 2011: 3'222'856 CHF

- 10.08-03.10 and 07.10-06.11 “*A forward genetic approach to uncover novel molecules required for NK cell function and CD8⁺ T cell priming*”; The Scripps Research Institute, Prof. Bruce Beutler
Swiss National Science Foundation, 18 + 12 months fellowship for advanced researchers
- 15.09.06-14.09.08 “*Identification and characterization of new molecular components of the innate immune system*”;
The Scripps Research Institute, Prof. Bruce Beutler
European Molecular Biology Organization (EMBO); 24 months fellowship
- 11.04.06-11.04.06 “*Identification and characterization of new molecular components of the innate immune system*”;
The Scripps Research Institute, Prof. Bruce Beutler
Swiss National Science Foundation/ETHZ, 12 months fellowship (gratefully declined)

Reviewer (journals) Ann NY Acad Sci, Proc Natl Acad Sci, Gastroenterology, Cell Death & Disease, J. Clin. Invest., EMBO Journal, EMBO reports, British Journal of Cancer, Clinical and Translational Medicine, British Journal of Haematology, OncoImmunology, Journal of Leukocyte Biology, Cancers, Allergy, Int Arch Allergy Immunol, Virus Research, Journal of Immunology Research, Mol Cancer Res, Cancer Med., Cellular Physiology and Biochemistry, Drugs of Today, JCI Insight, Clinical and Experimental Allergy, Journal of Experimental & Clinical Cancer Research, European Journal of Inflammation, European Journal of Immunology, Scientific Reports, The FEBS Journal, Technology in Cancer Research & Treatment, Microbiome, Cytokine, Journal of Experimental & Clinical Cancer Research, Clinical & Experimental Metastasis, International Journal of Molecular Sciences; International Immunopharmacology, Journal for ImmunoTherapy of Cancer, Review Commons.
Since 2014, Review Editor for Frontiers in Immunology, section Microbial Immunology.

Reviewer (foundations) Swiss Cancer League, French National Research Agency, Leukaemia & Lymphoma Research UK (Bloodwise), Medical Research Council (UK), Belgian Foundation against Cancer, Health Research Board (Ireland), The Kay Kendall Leukaemia Fund (UK), Israel Science Foundation, Worldwide Cancer Research, French National Cancer Institute (INCa; panel member of the Scientific Evaluation Committee in 2017, 2018 and 2020; invited assignment kindly declined for 2019).

Collaborations National:

Prof. Christoph Müller, Prof. Aurel Perren, Prof. Alessandro Lugli, Prof. Inti Zlobec, PD Dr. Yara Banz, Institute of Pathology, University of Bern
 Prof. Andrew Macpherson, University Hospital of Bern
 Prof. Adrian Ochsenbein, University Hospital of Bern
 Prof. Guido Beldi, University Hospital of Bern
 Prof. Markus G. Manz and PD Dr. Alexandre Theodorides, University Hospital Zurich
 Prof. Radek C. Skoda, University of Basel
 Prof. Nicolas Bonadies, PD Dr. Alicia Rovó, University Hospital of Bern
 Prof. B. Ludewig, Institute of Immunobiology, St-Gallen
 Prof. Christophe von Garnier, CHUV / University of Lausanne

International:

Prof. Bruce Beutler, UT Southwestern Medical Center, Dallas, TX, USA
 Prof. Kathy McCoy, University of Calgary, Canada
 Prof. Karl Lang, University of Duisburg-Essen, Essen, Germany
 Prof. Astrid Westendorf, University of Duisburg-Essen, Essen, Germany

Memberships

Swiss Biosafety Network (SBNet) since 2012
 Swiss Society for Allergology and Immunology (SSAI) since 2013
 European Academy of Tumor Immunology since 2016

Teaching

Yearly since 2013 Lecture for students of the Fachhochschule Bern on cellular pathology and inflammation
 Yearly since 2013 Lecture for a course on transgenic mouse technology, “Random mutagenesis”, for MSc and PhD students in life sciences, UniBE
 2013-2016 Lecture “Molecular mechanisms of inflammation” for medical students, UniBE
 Starting 2012 Member of the Expert Commission of the Graduate School for Cellular and Biomedical Sciences, University of Bern; mentor (total of 20 PhD students) and thesis co-advisor (total of 7 PhD students)
 Yearly since 2012 Lecture in molecular pathology “Animal models of diseases” for biology students, UniBE
 Yearly since 2012 Coordinator and lecturer of the course “Histology and general pathology for biology students”, UniBE
 Yearly since 2012 Tutor for Problem Based Learning (PBL) cases for medical students, UniBE
 2012-2016 Lecture “Cellular pathology” and “Molecular mechanisms of inflammation” for students in dental medicine, UniBE
 2012-2017 Co-organizer of the practical course in immunology for biology students, UniBE

Supervised students

BSc students (6 weeks) 2013: Langenegger Maya
 BSc students (10 weeks) 2017: Pascal Guntern
 2018: Benjamin Grädel
 2020: Silvio John Eugster
 MSc students (6 months) 2016-2017: Petra Polakova
 2019: Patrick von Delden
 2020: Margaux Bringardner
 MSc students (≥1 year) 2013-early 2015: Ivonne Koeck
 2013-early 2015: Marie-Hélène Wasmer
 2015-2016: Michael Berger
 2016-2018: Ioannis Kritikos
 Since 14.09.20: Silvio John Eugster
 Since 12.07.21: Océane Derivaz

 PhD students
 2011-2015 Lukas Mager, MD, awarded a Boehringer Ingelheim Fonds PhD fellowship and the 2016 Dr. Lutz Zwillenberg Prize of the University of Bern for his thesis project “*Molecular dissection of microbe-induced immunopathology*”
 2013-2017 Ludmila Cardoso-Alves, MSc
 2015-2018 Marie-Hélène Wasmer, MSc
 2016-2020 Lester Thoo, MSc

Since 01.10.18 Vivian Vu, MSc
Since 15.11.18 Wen Jie (Jeremy) Yeoh, MSc
Postdoctoral fellows
2015-2017 Lukas Mager, MD-PhD (Fellowship from Gertrud Hagmann Foundation)
2017-2018 Ludmila Cardoso-Alves, PhD
Since 14.09.20 Robert Anthony Gaultney, PhD (Seal of excellence for Marie Skłodowska-Curie fellowship application H2020-MSCA-IF-2020; score of 91%)

Diverse

Triathlon

39/235 age group / 235/1653 overall at Ironman World Championship (long distance triathlon); 9:53:29; 2009, Kailua-Kona, HI, USA
1/212 age group / 25/2076 overall at Ironman Arizona; 09:08:21; 2008, Tempe, AZ, USA
33/86 age group / 198/1688 overall at Ironman World Championship; 9:37:37; 2005, Kailua-Kona, HI, USA

Publication list – Philippe Krebs**Complete List of Published Work in MyBibliography:**

<https://www.ncbi.nlm.nih.gov/myncbi/philippe.krebs.1/bibliography/public/>
 or: <https://pubmed.ncbi.nlm.nih.gov/?term=krebs+philippe&sort=date>

Published Work**Research articles**

46. Sandra Ring, Jovana Cupovic, Lucas Onder, Mechthild Luetge, Christian Perez-Shibayama, Cristina Gil-Cruz, Elke Scandella, Angelina De Martin, Urs Mörbe, Fabienne Hartmann, Robert Wenger, Matthias Spiegl, Andrej Besse, Weldy Bonilla, Felix Stemeseder, Sarah Schmidt, Klaus Orlinger, **Philippe Krebs**, Burkhard Ludewig*, and Lukas Flatz*. *Viral vector-mediated reprogramming of the fibroblastic tumor stroma 1 sustains curative melanoma treatment.* **Nature communications.** 2021 Aug 5;12(1):4734. doi: 10.1038/s41467-021-25057-w.
45. Cupovic J, Ring SS, Onder L, Colston JM, Lütge M, Cheng HW, De Martin A, Provine NM, Flatz L, Oxenius A, Scandella E, **Krebs P**, Engeler D, Klenerman P, Ludewig B. *Adenovirus vector vaccination reprograms pulmonary fibroblastic niches to support protective inflating memory CD8+ T cells.* **Nat Immunol.** 2021 Aug;22(8):1042-1051. doi: 10.1038/s41590-021-00969-3. Epub 2021 Jul 15.
44. Ercolano G, Gomez-Cadena A, Dumauthioz N, Vanoni G, Kreutzfeldt M, Wyss T, Michalik L, Loyon R, Ianaro A, Ho PC, Borg C, Kopf M, Merkler D, **Krebs P**, Romero P, Trabanelli S, Jandus C. *PPAR γ drives IL-33-dependent ILC2 pro-tumoral functions.* **Nature communications.** 2021 May 5;12(1):2538. doi: 10.1038/s41467-021-22764-2.
43. Adamczyk A, Pastille E, Kehrmann J, Vu VP, Geffers R, Wasmer MH, Kasper S, Schuler M, Lange CM, Muggli B, Rau TT, Klein D, Hansen W, **Krebs P**, Buer J, Westendorf AM. *GPR15 facilitates the recruitment of regulatory T cells to promote colorectal cancer.* **Cancer Res.** 2021 Jun 1;81(11):2970-2982. doi: 10.1158/0008-5472.CAN-20-2133. Epub 2021 Mar 16.
42. Palmieri V, Ebel JF, Ngo Thi Phuong N, Klopffleisch R, Vu VP, Adamczyk A, Zöllner J, Riedel C, Buer J, **Krebs P**, Hansen W, Pastille E, Westendorf AM. *Interleukin-33 signaling exacerbates experimental infectious colitis by enhancing gut permeability and inhibiting protective Th17 immunity.* **Mucosal Immunol.** 2021 Jul;14(4):923-936. doi: 10.1038/s41385-021-00386-7. Epub 2021 Mar 2.
41. Duhan V, Khairnar V, Kitanovski S, Hamdan TA, Klein AD, Lang J, Ali M, Adomati T, Bhat H, Friedrich SK, Li F, **Krebs P**, Futerman AH, Addo MM, Hardt C, Hoffmann D, Lang PA, Lang KS. *Integrin alpha E (CD103) limits virus-induced IFN-I production in conventional dendritic cells* **Front. Immunol.** 2021 Jan 27;11:607889. doi: 10.3389/fimmu.2020.607889. eCollection 2020.
40. Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, Stalman USA, Büsche G, Kreipe H, Gütgemann I, **Krebs P**, Banz Y, Boor P, Tai EW, Brümmendorf TH, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG, Schneider RK. *Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis.* **Cell Stem Cell.** 2021 Apr 1;28(4):637-652.e8. doi: 10.1016/j.stem.2020.11.004. Epub 2020 Dec 9.
39. Lee S, Sears MJ, Zhang Z, Li H, Salhab I, **Krebs P**, Xing Y, Nah HD, Williams T, Carstens RP. *Cleft lip and cleft palate in Esrp1 knockout mice is associated with alterations in epithelial-mesenchymal crosstalk.* **Development.** 2020 Apr 30;147(21):dev187369. doi: 10.1242/dev.187369
38. Cardoso Alves L, Berger MD, Koutsandreas T, Kirschke N, Lauer C, Spörri R, Chatziioannou A, Corazza N, **Krebs P** *Non-apoptotic TRAIL function modulates NK cell activity during viral infection.* **EMBO Rep.** 2020 Jan 7;21(1):e48789. doi: 10.15252/embr.201948789. Epub 2019 Nov 19.
#senior and corresponding author

37. Pastille E, Wasmer MH, Adamczyk A, Vu VP, Mager L, Phuong NNT, Palmieri V, Simillion C, Hansen W, Kasper S, Schuler M, Muggli B, McCoy KD, Buer J, Zlobec I, Westendorf AM#, **Krebs P#**.
The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer.
Mucosal Immunol. 2019 Jul;12(4):990-1003. doi: 10.1038/s41385-019-0176-y. Epub 2019 Jun 5.
#shared senior and corresponding authors
36. Schürch CM, Roelli MA, Forster S, Wasmer MH, Brühl F, Maire RS, Di Pancrazio S, Ruepp MD, Giger R, Perren A, Schmitt AM, **Krebs P**, Charles RP, Dettmer MS
Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by macrophages and is a promising therapeutic strategy.
Thyroid. 2019 Jul;29(7):979-992. doi: 10.1089/thy.2018.0555. Epub 2019 May 10.
35. Saurer L, Zysset D, Rihs S, Mager L, Gusberti M, Simillion C, Lugli A, Zlobec I, **Krebs P#**, Mueller C#. *TREM-1 promotes intestinal tumorigenesis.*
Sci Rep. 2017 Nov 1;7(1):14870. doi: 10.1038/s41598-017-14516-4.
#shared senior and corresponding authors
34. Mager LF, Koelzer VH, Stuber R, Thoo L, Keller I, Koeck I, Langenegger M, Simillion C, Pfister SP, Faderl M, Genitsch V, Tcymbarevich I, Juillerat P, Li X, Xia Y, Karamitopoulou E, Lyck R, Zlobec I, Hapfelmeier S, Bruggmann R, McCoy KD, Macpherson AJ, Müller C, Beutler B, **Krebs P#**.
The ESRP1-GPR137 axis contributes to intestinal pathogenesis.
Elife. 2017 Oct 4;6. pii: e28366. doi: 10.7554/eLife.28366.
#senior and corresponding author
33. Wiedmer T, Blank A, Pantasis S, Normand L, Bill R, **Krebs P**, Tschan MP, Marinoni I, Perren A.
Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via a lysosome-dependent mechanism.
Mol Cancer Ther. 2017 Nov;16(11):2502-2515. doi: 10.1158/1535-7163.MCT-17-0136.
32. Siggs OM, Popkin DL, **Krebs P**, Li X, Tang M, Zhan X, Zeng M, Lin P, Xia Y, Oldstone MB, Cornall RJ, Beutler B.
Mutation of the ER retention receptor KDELR1 leads to cell-intrinsic lymphopenia and a failure to control chronic viral infection.
Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5706-14.
31. Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, Joller S, Murdoch JR, Brümmendorf T, Genitsch V, Lugli A, Cathomas G, Moch H, Weber A, Zlobec I, Junt T, **Krebs P#**.
The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice.
Oncoimmunology. 2015 Jun 26;5(1).
#senior and corresponding author
30. Mager LF, Riether C, Schürch CM, Banz Y, Wasmer MH, Stuber S, Theocharides AP, Li X, Xia Y, Saito H, Nakae S, Baerlocher GM, Manz MG, McCoy KD, Macpherson AJ, Ochsenbein AF, Beutler B, **Krebs P#**.
IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.
J Clin Invest. 2015 Jul 1;125(7):2579-91
#senior and corresponding author
Recommended by F1000Prime Faculty
29. Arnold CN, Barnes MJ, Berger M, Blasius AL, Brandl K, Croker B, Crozat K, Du X, Eidenschenk C, Georgel P, Hoebe K, Huang H, Jiang Z, **Krebs P**, La Vine D, Li X, Lyon S, Moresco EM, Murray AR, Popkin DL, Rutschmann S, Siggs OM, Smart NG, Sun L, Tabeta K, Tomisato W, Webster V, Won S, Xia Y, Xiao N, Beutler B.
ENU-induced phenovariance in mice: inferences from 587 mutations.
BMC Res Notes. 2012 Oct 24;5(1):577.
28. Blasius AL, **Krebs P**, Sullivan BM, Oldstone MB, Popkin DL.
Slc15a4, a gene required for pDC sensing of TLR ligands, is required to control persistent viral infection.
PLoS Pathog. 2012 Sep;8(9)
27. Wingender G, Stepniak D, **Krebs P**, Lin L, McBride S, Wie B, Braun J, Mazmanian SK, Kronenberg M.
Intestinal microbes modulate the phenotype and function of mouse invariant Natural Killer T cells.
Gastroenterology. 2012 Aug;143(2):418-28.

26. **Krebs P**, Fan W, Chen YH, Tobita K, Downes MR, Wood MR, Sun L, Li X, Xia Y, Ding N, Spaeth JM, Moresco EM, Boyer TG, Lo CW, Yen J, Evans RM, Beutler B.
Lethal mitochondrial cardiomyopathy in a hypomorphic Med30 mouse mutant is ameliorated by ketogenic diet.
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19678-82. Epub 2011 Nov 21.
"Commentaries on Cutting Edge Science" in Circ Res. 2012 Apr 13;110(8):1047-8.
25. Krieg L, Milstein O, **Krebs P**, Xia Y, Beutler B, Du X.
Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice.
Blood. 2011 Dec 8;118(24):6418-25. Epub 2011 Oct 5.
24. **Krebs P***, Crozat K*, Popkin D, Oldstone MB and Beutler B.
Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice.
Blood. 2011 Jun 16;117(24):6582-8.
***first shared**
Recommended by F1000Prime Faculty
23. Crozat K, Eidenschenck C, Jaeger B, **Krebs P**, Guia S, Beutler B, Vivier E, and Ugolini S
Impact of β 2 integrin deficiency on mouse Natural Killer cell development and function.
Blood. 2011 Mar 10;117(10):2874-82.
22. Wingender G, **Krebs P**, Beutler B, Kronenberg M
Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178 dependent and is correlated with antigenic potency.
J Immunol. 2010 Sep 1;185(5):2721-9.
21. Freigang S, Zadorozhny V, McKinney MK, **Krebs P**, Herro R, Pawlak J, Kain L, Schrantz N, Masuda K, Liu Y, Savage PB, Bendelac A, Cravatt BF, Teyton L.
Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice.
J Clin Invest. 2010 Jun 1;120(6):1873-84.
20. Eidenschenk C, Crozat K, **Krebs P**, Arens R, Popkin D, Arnold CN, Blasius AL, Benedict CA, Moresco EM, Xia Y, Beutler B.
Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells.
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9759-64.
19. Berger M, **Krebs P**, Crozat K, Li X, Croker BA, Popkin D, Du X, Lawson BR, Theofilopoulos AN, Xia Y, Khovananth K, Moresco EM, Satoh T, Takeuchi O, Akira S, and Beutler BA
A Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence.
Nat Immunol. 2010 Apr;11(4):335-43.
Recommended by F1000Prime Faculty
18. Barnes MJ, Aksoylar H, **Krebs P**, Bourdeau T, Arnold CN, Xia Y, Khovananth K, Engel I, Sovath S, Lampe L, Laws E, Kronenberg M, Steinbrecher K, Hildeman D, Leighton Grimes H, Beutler B, and Hoebe K
Loss of T and B cell quiescence and development of flora-dependent wasting disease and intestinal inflammation in Gimap5-deficient mice.
J Immunol. 2010 Apr 1;184(7):3743-54.
17. Siggs OM, Berger M, **Krebs P**, Arnold C, Eidenschenk C, Huber C, Pirie E, Smart NG, Khovananth K, Xia Y, and Beutler BA
A mutation of Ikbkg causes immune deficiency without impairing degradation of I κ B α .
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3046-51.
16. Bolinger B, Engeler D, **Krebs P**, Miller S, Firner S, Hoffmann M, Palmer DC, Restifo NP, Tian Y, Clavien PA, Ludwig B
IFN γ -receptor signaling ameliorates transplant vasculopathy through attenuation of CD8 $^{+}$ T cell-mediated injury of vascular endothelial cells.
Eur J Immunol. 2010 Mar;40(3):733-43.
15. Xiao N, Eidenschenk C, Krebs P, Brandl K, Blasius AL, Xia Y, Khovananth K, Smart NG, Beutler B.
The Tpl2 Mutation Sluggish Impairs Type I IFN Production and Increases Susceptibility to Group B Streptococcal Disease.
J Immunol. 2009 Dec 15;183(12):7975-83.

14. **Krebs P**#, Barnes MJ, Lampe K, Whitley K, Bahjat KS, Beutler B, Janssen E, Hoebe K#. *NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses.* **Blood.** 2009 Jun 25;113(26):6593-602.
#Co-corresponding author
13. Barnes MJ, **Krebs P**, Harris N, Eidenschenk C, Gonzalez-Quintal R, Arnold CN, Crozat K, Sovath S, Moresco EM, Theofilopoulos AN, Beutler B, Hoebe K. *Commitment to the regulatory T cell lineage requires CARMA1 in the thymus but not in the periphery.* **PLoS Biol.** 2009 Mar 3;7(3):e51.
12. Blasius AL, Brandl K, Crozat K, Xia Y, Khovananth K, **Krebs P**, Smart NG, Zampolli A, Ruggeri ZM, Beutler BA. *Mice with mutations of Dock7 have generalized hypopigmentation and white-spotting but show normal neurological function.* **Proc Natl Acad Sci U S A.** 2009 Feb 24;106(8):2706-11
11. Zinkernagel MS, Bolinger B, **Krebs P**, Onder L, Miller S, Ludewig B. *Immunopathological basis of lymphocytic choriomeningitis virus-induced chorioretinitis and keratitis.* **J Virol.** 2009 Jan;83(1):159-66.
10. Bolinger B*, **Krebs P***, Tian Y, Engeler D, Scandella E, Miller S, Palmer DC, Restifo NP, Clavien PA, Ludewig B. *Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen.* **Blood.** 2008 May 1;111(9):4588-95. Epub 2008 Jan 14
***first shared**
Comment in Blood. 2008 May 1;111(9):4426-7.
9. **Krebs P**, Scandella E, Bolinger B, Engeler D, Miller S, Ludewig B. *Chronic immune reactivity against persisting microbial antigen in the vasculature exacerbates atherosclerotic lesion formation.* **Arterioscler Thromb Vasc Biol.** 2007 Oct;27(10):2206-13.
8. **Krebs P**, Kurrer MO, Kremer M, De Giuli R, Sonderegger I, Henke A, Maier R, Ludewig B. *Molecular mapping of autoimmune B cell responses in experimental myocarditis.* **J Autoimmun.** 2007 Jun;28(4):224-33.
7. Maier R, Miller S, Kurrer M, **Krebs P**, de Giuli R, Kremer M, Scandella E, Ludewig B. *Quantification and characterization of myosin peptide-specific CD4+ T cells in autoimmune myocarditis.* **J Immunol Methods.** 2005 Sep;304(1-2):117-2
6. **Krebs P**, Scandella E, Odermatt B, Ludewig B. *Rapid functional exhaustion and deletion of cytotoxic T lymphocytes following immunization with recombinant adenovirus.* **J Immunol.** 2005 Apr 15;174(8):4559-66.
5. Baker CTH., Bocharov G, Ford JM, Lumb PM, Norton SJ, Paul CAH, **Krebs P**, Junt T, and Ludewig B. *Computational approaches to parameter estimation and model selection in immunology.* **Journal of Computational and Applied Mathematics**, 184 (2005) 50-76
4. Junt T, Scandella E, Forster R, **Krebs P**, Krautwald S, Lipp M, Hengartner H, Ludewig B. *Impact of CCR7 on priming and distribution of antiviral effector and memory CTL.* **J Immunol.** 2004 Dec 1;173(11):6684-93.
3. Ludewig B*, **Krebs P***, Metters H, Tatzel J, Tureci O, Sahin U. *Molecular characterization of virus-induced autoantibody responses.* **J Exp Med.** 2004 Sep 6;200(5):637-46.
***first shared**
Recommended by F1000Prime Faculty
2. Ludewig B, **Krebs P**, Junt T, Metters H, Ford NJ, Anderson RM, Bocharov G. *Determining control parameters for dendritic cell-cytotoxic T lymphocyte interaction.* **Eur J Immunol.** 2004 Sep;34(9):2407-18.

1. Bocharov G, Ludewig B, Bertoletti A, Klenerman P, Junt T, **Krebs P**, Luzyanina T, Fraser C, Anderson RM. *Underwhelming the immune response: effect of slow virus growth on CD8+-T-lymphocyte responses.* **J Virol.** 2004 Mar;78(5):2247-54.

Review articles

8. Ludmila Cardoso Alves, Nadia Corazza, Olivier Micheau, **Philippe Krebs#**
The multifaceted role of TRAIL signaling in cancer and immunity.
FEBS J. 2020 Nov 20. doi: 10.1111/febs.15637. Online ahead of print.
#senior and corresponding author
7. Thoo L, Noti M, **Krebs P#**
Keep calm: The intestinal barrier at the interface of peace and war.
Cell Death Dis. 2019 Nov 7;10(11):849. doi: 10.1038/s41419-019-2086-z. Review.
#senior and corresponding author
6. Wasmer MHC, **Krebs P#**
The role of IL-33-dependent inflammation in the tumor microenvironment.
Front Immunol. 2017 Jan 9;7:682. Review.
#senior and corresponding author
5. Mager LF, Wasmer MH, Rau TT, **Krebs P#**.
Cytokine-induced Modulation of Colorectal Cancer.
Front Oncol. 2016 Apr 19;6:96. Review.
#senior and corresponding author
4. Ludewig B, **Krebs P**, Scandella E.
Immunopathogenesis of atherosclerosis.
J Leukoc Biol. 2004 Aug;76(2):300-6. Epub 2004 Mar 23. Review.
3. Maier R, **Krebs P**, Ludewig B.
Immunopathological basis of virus-induced myocarditis.
Clin Dev Immunol. 2004 Mar;11(1):1-5. Review.
2. Ludewig B, **Krebs P**, Junt T, Bocharov G.
Dendritic cell homeostasis in the regulation of self-reactivity.
Curr Pharm Des. 2003;9(3):221-31. Review.
1. **Krebs P**, Kurrer M, Sahin U, Tureci O, Ludewig B.
Autoimmunity seen through the SEREX-scope.
Autoimmun Rev. 2003 Oct;2(6):339-45. Review.

Book chapters

2. **Krebs P**, Ludewig B
A transgenic mouse model for virus-induced vasculitis.
A Handbook of Mouse Models of Cardiovascular Disease, John Wiley Sons Ltd, 2006
Book chapter (edited by Quingbo Xu)
1. **Krebs P**, Ludewig B
How Transgenic Mouse Models Contribute to a Better Understanding of Virus-induced Autoimmunity.
Infections and autoimmunity, Elsevier, 2004
Book chapter (edited by Yehuda Shoenfeld and Noel R. Rose)